Reuben J Broom

Reuben J Broom

UNVERIFIED PROFILE

Are you Reuben J Broom?   Register this Author

Register author
Reuben J Broom

Reuben J Broom

Publications by authors named "Reuben J Broom"

Are you Reuben J Broom?   Register this Author

11Publications

144Reads

-Profile Views

Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma.

Asia Pac J Clin Oncol 2015 Sep 6;11(3):e1-5. Epub 2015 Jan 6.

Auckland City Hospital, Auckland, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12296DOI Listing
September 2015

Analysis of molecular cytogenetic changes in metastatic renal cell carcinoma in the setting of everolimus treatment: a pilot project.

Clin Genitourin Cancer 2014 Aug 9;12(4):256-61. Epub 2014 Jan 9.

Adult Oncology Research Centre, Department of Medical Oncology, Auckland City Hospital, Auckland, New Zealand. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.01.002DOI Listing
August 2014

Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.

Clin Genitourin Cancer 2014 Aug 21;12(4):e143-6. Epub 2014 Feb 21.

Department of Medical Oncology, Auckland City Hospital, Auckland, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.02.002DOI Listing
August 2014

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.

J Cancer Res Clin Oncol 2013 Nov 14;139(11):1917-26. Epub 2013 Sep 14.

University of Ioannina, Ioannina, Greece,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-013-1510-5DOI Listing
November 2013

Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status.

Clin Genitourin Cancer 2012 Sep 21;10(3):202-6. Epub 2012 Mar 21.

Department of Medical Oncology, Regional Cancer and Blood Service, Auckland City Hospital, Auckland, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2012.01.008DOI Listing
September 2012

Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonate therapy in patients with metastatic breast cancer.

Support Cancer Ther 2007 Sep;4(4):182-7

Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/SCT.2007.n.013DOI Listing
September 2007

A durable complete remission between two isolated presentations of metastatic breast cancer, the second with intracardiac disease.

Clin Breast Cancer 2006 Jun;7(2):162-3

Department of Medical Oncology, Regional Cancer and Blood Service, Auckland City Hospitial, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2006.n.027DOI Listing
June 2006